Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Josh Duhamel's secret to the good life at 53? Wolverine peptides, ditching Hollywood and having another baby. - 2Pick Your #1 Kind Of Treat
- 3To fix a patient's irregular heartbeat, doctors first tested its digital 'twin'
- 4Grass Care Administrations for a Wonderful, Sound Yard
- 5The Best Games On the planet
- Russia Fields New Ulan-2 All-Terrain Tactical Vehicle
- Kiev declares energy emergency after Russian attacks amid winter cold
- A definitive Frozen yogurt Standoff: Which Flavor Rules?
- Find the Force of The ability to understand anyone on a deeper level: Improving Mindfulness and Connections
- African nations push to recognize crimes of colonialism in Algeria
- As Western heat wave ends, scientists try to make sense of its length and intensity
- Takeda's AI-crafted psoriasis pill succeeds in late-stage studies
- Israel halts defense sales to France, citing 'hostile attitude,' sources tell 'Post'
- Vote in favor of Your Number one Smartwatch: Exactness and Style Matter
